Fig. 4

(A) Performance for models from younger patients to predict in older patients and models from older patients to predict in younger patients. (B) Percent of blast cells in bone marrow and peripheral blood samples. (C) Number of younger and older patients with mutations and fusion genes in favorable and adverse risk. p-values in (B) and (C) from Wilcoxon test: ‘****’: \(p \le 0.0001\); ‘***’: \(p \le 0.001\) ; ‘**’: \(p \le 0.01\); ‘*’: \(p \le 0.05\); ‘ ‘: \(p > 0.05\).